Skip to main content

Gynecologic Cancers

Health insurance coverage mediated racial and ethnic inequities among patients with advanced-stage cervical cancer, according to findings from a recent retrospective, cross-sectional, population-based study. Read More ›

The small molecule inhibitor of tyrosine kinase WEE1 adavosertib demonstrated promising clinical activity in a single-arm, phase 2 study of patients with unselected uterine serous cancer (USC), with an objective response rate of 29.4%, said Joyce F. Liu, MD, MPH, Director of Clinical Research, Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, at the ASCO 2020 virtual annual meeting. Read More ›

Chicago, IL—Oral cediranib, an investigational vascular endothelial growth factor (VEGF) inhibitor, in combination with a PARP inhibitor or with chemotherapy, shows survival benefit in women with relapsed platinum-sensitive ovarian cancer, according to findings from 2 clinical trials presented at the 2017 ASCO annual meeting. Read More ›

The PARP inhibitor veliparib demonstrated activity in relapsed/refractory BRCA-mutated ovarian cancer, according to results from a phase 2 trial conducted by the Gynecologic Oncology Group. Read More ›

Two phase 3 trials presented at the 2013 European Cancer Congress suggest that the optimal role of bevacizumab will be in high-risk patients. Read More ›

A new antiangiogenesis inhibitor with a different mechanism of action than bevacizumab shows promise in platinum-sensitive ovarian cancer, according to results of the phase 3 TRINOVA-1 trial presented at the 2013 meeting of the European Cancer Congress. Read More ›

Angiogenesis is an active area of clinical research in ovarian cancer, but proving that this approach extends overall survival (OS) has been somewhat challenging thus far. Michael Bookman, MD, reviewed studies of antiangiogenesis in high-grade serous ovarian cancer at the 2013 Chemotherapy Foundation Symposium, held in New York City. Read More ›

Ovarian cancer is the fifth leading cause of cancer-related death in females in the United States.1 There will be an estimated 22,280 new cases and 15,500 deaths related to ovarian cancer in 2012.1 The prognosis of advanced ovarian cancer is poor, with a 5-year survival rate of 5% to 20%. A platinum-based doublet chemotherapy post cytoreductive surgery has been the standard of care for the past decade. Read More ›

Late-stage ovarian cancer patients responded well to an experimental carboplatin/decitabine combination therapy, even though they had become resistant to carboplatin, Indiana University researchers report. Furthermore, the researchers believe they have discovered biomarkers that could assist in identifying patients who are most likely to benefit from this therapy. 

Read More ›

Over the past year, data regarding 2 specific ovarian cancer management strategies have generated considerable interest within the clinical gynecologic cancer community among patients, clinicians, and re - searchers. One strategy involves the use of bevacizumab (Avastin), and the other approach centers on poly(ADPribose) polymerase (PARP) inhibitors.

Read More ›

Page 1 of 2